Alinity m HIV-1 Assay

Alinity_m_HIV_1_AMP_KIT_US.jpg


Assay design that addresses today's challenges and safeguards for the future in detecting HIV groups/subtypes, as well as emerging strains, is critical to aid in HIV patient management. The Alinity m HIV-1 assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the detection and quantification of Human Immunodeficiency Virus type 1 (HIV-1) RNA on the automated Alinity m System for confirmation of HIV-1 infection or for monitoring.

  • Dual target design ensures detection of current strain and safeguards against viral evolution
  • Robust quality program including Abbott Global Surveillance Program monitors assay performance against emerging strains
  • High sensitivity and excellent precision meet clinical guidelines and provide confidence in results.
  • High correlation with the m2000 RealTime HIV assay.

icon-link.pngInstructions for Use

VIEW ORDERING INFORMATION

Product Details
 

INTENDED USE

The Alinity m HIV-1 assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the detection and quantification of Human Immunodeficiency Virus type 1 (HIV-1) RNA on the automated Alinity m System for confirmation of HIV-1 infection or for monitoring HIV-1 infected individuals. The Alinity m HIV-1 assay is intended for use in the clinical management of HIV-1 infected individuals in conjunction with clinical presentation and other laboratory markers.

The Alinity m HIV-1 assay is intended for use to monitor disease prognosis by measuring baseline plasma HIV-1 RNA levels and to assess response to antiretroviral treatment by measuring changes in plasma HIV-1 RNA levels. Performance for quantitative monitoring is not established with serum specimens.

The Alinity m HIV-1 assay is also intended for use as a supplemental test to confirm HIV-1 infection in individuals who have reactive results with HIV immunoassays. Performance for supplemental use is established with both plasma and serum specimens.

The results from the Alinity m HIV-1 assay must be interpreted within the context of all relevant clinical and laboratory findings.

This device is not intended for use as a first line diagnostic test or for screening donors of blood, blood products, or human cells or tissues, or cellular and tissue-based products (HCT/Ps).

LIMITATIONS OF THE PROCEDURE

  • Optimal performance of this test requires appropriate specimen collection and handling (refer to the SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS section of the package insert.)
  • Only human serum (including SST) and plasma (ACD, K2 EDTA, K3 EDTA, and PPT) specimens can be used with the Alinity m HIV-1 assay. The use of other anticoagulants have not been evaluated.
  • Debris within plasma and serum specimens (eg, clots, fibrin strands) may interfere with sample processing.
  • Performance of the supplemental test to confirm HIV-1 infection in individuals who have reactive results with HIV immunoassays was established for HIV-1 viral load at ≥100 Copies/mL.
  • Diluted specimens must be tested within 2 hours after dilution and should not be frozen.
  • If the HIV-1 results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.
  • HIV-1 RNA concentration (ie, number of virus particles present in the samples) may be affected by patient factors (age, presence of symptoms) and/or stage of infection.
  • Though rare, mutations within the highly conserved regions of a viral genome detected by Alinity m HIV-1 may affect primers and/or probe binding resulting in the under-quantitation of virus or failure to detect the presence of virus. To ensure assay robustness, the Alinity m HIV-1 assay is designed to target two highly conserved sequences within the HIV-1 genome.
  • Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to evaluate technology differences. Users should follow their own specific policies/procedures.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the calibrators, positive controls, or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in the package insert.
  • Assay linearity for HIV-1 Group M subtype BF, subtype H and Group N quantification was tested up to 10,000 Copies/mL for subtype BF, 300,000 Copies/mL for subtype H, and 1,000,000 Copies/mL for Group N, respectively.

For in vitro diagnostic use. Rx Only.

specifications
 

 

ABBOTT ALINITY m HIV-1 ASSAY PERFORMANCE1-5
Technology RT-PCR
Time to First Result < 115 min
Throughput Up to 1,080 samples in 24 hours*
Claim Monitoring† and confirmatory
Standardization World Health Organization (WHO) 3rd HIV-1 International Standard (NIBSC code: 10/152 group M subtype B)
Probe Design Partially double stranded DNA probe design
Target Region Dual Target: Integrase and LTR
Groups and Subtypes Group M subtypes (A, BF, C, D, CRF01-AE, F, CRF02-AG, G and H), Group O, Group N
Specimen Types Plasma: Acid Citrate Dextrose (ACD); K2 EDTA; K3 EDTA; plasma preparation tubes (PPTs**)
Serum: Serum; Serum Separator Tube (SST**)
Sensitivity
Limit of Detection (LoD)
Plasma
20 Copies/mL (1.30 Log Copies/mL)
Probit analysis determined that the concentration of HIV-1 RNA detected with 95% probability was 13.99 Copies/mL
(95% CI: 11.69 to 19.22 Copies/mL)
Sensitivity
Limit of Detection (LoD)
Serum
20 Copies/mL (1.30 Log Copies/mL)
Probit analysis determined that the concentration of HIV-1 RNA detected with 95% probability was 15.94 Copies/mL
(95% CI:13.30 to 21.53 Copies/mL)
Linearity 20 to 10,000,000 Copies/mL
Result Units Copies/mL, Log [Copies/mL], IU/mL or Log [IU/mL]
Sample Input Volume 0.6 mL
Specificity The overall specificity for plasma and serum combined was 100.0% (95% CI: 99.3 to 100.0%).
Controls Negative, low positive and high positive controls — single-use tubes
Calibrator 2 calibrator levels — single-use tubes
Internal Control Armored RNA®
*Number of actual samples per 24-hour period may vary based on laboratory practice and workflow.
†Performance for quantitative monitoring is not established with serum specimens.
**Gel tubes.

REFERENCES
1. Alinity m HIV-1 AMP Kit Package Insert (PI): 53-608158/R3.
2. Alinity m HIV-1 CAL Kit Package Insert 53-608159/R2.
3. Alinity m HIV-1 CTRL Kit Package Insert 53-608160/R2.
4. Alinity m Operations Manual 54-605001/R10.
5. Abbott. Data on File.

Ordering Info

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No